GlassScriptPhysician profile
Ben-Gary Harvey
NPI 1194812289
$9,433.48
in general payments reported to CMS, 2019-2025
13 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,467 · 2020: $276 · 2021: $1,128 · 2022: $3,980 · 2023: $626 · 2024: $497 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,158.85 | 2019-2023 | Da Vinci Surgical System |
| Pulmonx Corporation | $1,634.97 | 2019-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Covidien LP | $1,148.08 | 2019-2020 | |
| Olympus Corporation of The Americas | $812.54 | 2019 | |
| Ethicon INC. | $789.19 | 2021 | |
| Galvanize Therapeutics, INC | $436.65 | 2025 | Aliya System |
| Medtronic, INC. | $264.20 | 2021 | |
| Glaxosmithkline, LLC. | $57.59 | 2019 | |
| United Therapeutics Corporation | $47.50 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.57 | 2024-2025 | Xifaxan |
| Genzyme Corporation | $15.07 | 2021 | |
| Mylan Specialty L.P. | $11.71 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben-Gary Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.